Business
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) --
About this update from Femasys Inc.
[{"type":"text","content":"-- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment -- ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today that it has received notice from the American Medical Association (AMA) CPT Editorial Panel approving a new, unique Category III Current Procedural Terminology (CPT) code covering the use of FemaSeed for intratubal insemination (ITI), a procedure that delivers sperm directly into the fallopian tube where conception occurs. The approved Category III CPT code is expected to be issued publicly by the AMA with an effective date of January 1, 2027. Approval of this Category III CPT code represents an important step in advancing the reimbursement strategy for FemaSeed to support broader clinical adoption, provider utilization, and expanded patient access to this first-step infertility treatment option. “The creation of a new Category III code for the FemaSeed ITI procedure reflects the innovation and differentiated approach of our technology,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “As we initiate the rollout of FemaSeed to gynecologists and their clinical teams, supported by the availability of our FemSperm® product line, we intend to expand our provider footprint, accelerate adoption, and increase access to care for more than 10 million women in the U.S. affected by infertility. Together, these offerings advance our scalable commercialization strategy and position us for sustainable long-term growth.” FemaSeed is a next-generation artificial insemination solution that enhances fertilization by precisely delivering sperm to the fallopian tube, the natural site of conception. Developed to bridge the gap between traditional intrauterine insemination (IUI), which often has low success rates, and in vitro fertilization (IVF), which is costly and invasive, FemaSeed offers a safe, effective, accessible, and cost-efficient first-line, in-office treatment option. In its pivotal clinical trial (NCT0468847), conducted in the challenging setting of low male sperm count, FemaSeed achieved more than double the pregnancy rates of IUI.1 FemaSeed is authorized for use in the U.S...